IDEXX LABORATORIES INC /DE Excess Tax Benefit from Share-based Compensation, Financing Activities
IDEXX LABORATORIES INC /DE (IDXX) reported Excess Tax Benefit from Share-based Compensation, Financing Activities of $0 for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-15.
Discontinued › Notes › Compensation Related Costs
us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities · last filed 2019-02-15
- IDEXX LABORATORIES INC /DE excess tax benefit from share-based compensation, financing activities for the quarter ending 2016-12-31 was $4.48M, a 252.24% increase year-over-year.
- IDEXX LABORATORIES INC /DE excess tax benefit from share-based compensation, financing activities for the quarter ending 2016-09-30 was $5.43M, a 318.64% increase year-over-year.
- IDEXX LABORATORIES INC /DE excess tax benefit from share-based compensation, financing activities for the quarter ending 2016-06-30 was $2.73M, a 164.09% increase year-over-year.
- IDEXX LABORATORIES INC /DE excess tax benefit from share-based compensation, financing activities for the quarter ending 2016-03-31 was $2.06M, a 73.25% decline year-over-year.
- IDEXX LABORATORIES INC /DE excess tax benefit from share-based compensation, financing activities for fiscal 2018 was $0.00.
- IDEXX LABORATORIES INC /DE excess tax benefit from share-based compensation, financing activities for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
- IDEXX LABORATORIES INC /DE excess tax benefit from share-based compensation, financing activities for fiscal 2016 was $14.70M, a 29.93% increase from fiscal 2015.
- IDEXX LABORATORIES INC /DE excess tax benefit from share-based compensation, financing activities for fiscal 2015 was $11.31M, a 29.62% decline from fiscal 2014.
| Period end | Excess Tax Benefit from Share-based Compensation, Financing Activities 3 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 6 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 9 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 10-K · filed 2019-02-15 | |||
| 2017-12-31 | $0.00 10-K · filed 2019-02-15 | |||
| 2016-12-31 | $4.48M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-15 | $9.91M derived: sum of 2 quarters · filed 2019-02-15 | $12.64M derived: sum of 3 quarters · filed 2019-02-15 | $14.70M 10-K · filed 2019-02-15 |
| 2016-09-30 | $5.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-31 | $8.16M derived: sum of 2 quarters · filed 2017-10-31 | $10.22M 10-Q · filed 2017-10-31 | $11.50M derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-06-30 | $2.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-01 | $4.79M 10-Q · filed 2017-08-01 | $6.06M derived: sum of 3 quarters · filed 2018-02-16 | $7.36M derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-03-31 | $2.06M 10-Q · filed 2017-04-28 | $3.33M derived: sum of 2 quarters · filed 2018-02-16 | $4.63M derived: sum of 3 quarters · filed 2018-02-16 | $5.67M derived: sum of 4 quarters · filed 2018-02-16 |
| 2015-12-31 | $1.27M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $2.57M derived: sum of 2 quarters · filed 2018-02-16 | $3.60M derived: sum of 3 quarters · filed 2018-02-16 | $11.31M 10-K · filed 2018-02-16 |
| 2015-09-30 | $1.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-01 | $2.33M derived: sum of 2 quarters · filed 2016-11-01 | $10.04M 10-Q · filed 2016-11-01 | $16.54M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-06-30 | $1.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-02 | $8.75M 10-Q · filed 2016-08-02 | $15.24M derived: sum of 3 quarters · filed 2017-02-17 | $16.86M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-03-31 | $7.71M 10-Q · filed 2016-04-29 | $14.21M derived: sum of 2 quarters · filed 2017-02-17 | $15.83M derived: sum of 3 quarters · filed 2017-02-17 | $17.04M derived: sum of 4 quarters · filed 2017-02-17 |
| 2014-12-31 | $6.50M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $8.12M derived: sum of 2 quarters · filed 2017-02-17 | $9.33M derived: sum of 3 quarters · filed 2017-02-17 | $16.08M 10-K · filed 2017-02-17 |
| 2014-09-30 | $1.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-28 | $2.83M derived: sum of 2 quarters · filed 2015-10-28 | $9.58M 10-Q · filed 2015-10-28 | $16.30M derived: sum of 4 quarters · filed 2016-02-17 |
| 2014-06-30 | $1.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-30 | $7.96M 10-Q · filed 2015-07-30 | $14.68M derived: sum of 3 quarters · filed 2016-02-17 | $16.29M derived: sum of 4 quarters · filed 2016-02-17 |
| 2014-03-31 | $6.75M 10-Q · filed 2015-04-28 | $13.47M derived: sum of 2 quarters · filed 2016-02-17 | $15.07M derived: sum of 3 quarters · filed 2016-02-17 | $15.60M derived: sum of 4 quarters · filed 2016-02-17 |
| 2013-12-31 | $6.72M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-17 | $8.33M derived: sum of 2 quarters · filed 2016-02-17 | $8.85M derived: sum of 3 quarters · filed 2016-02-17 | $14.16M 10-K · filed 2016-02-17 |
| 2013-09-30 | $1.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-24 | $2.13M derived: sum of 2 quarters · filed 2014-10-24 | $7.44M 10-Q · filed 2014-10-24 | $11.93M derived: sum of 4 quarters · filed 2015-02-17 |
| 2013-06-30 | $520.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-25 | $5.83M 10-Q · filed 2014-07-25 | $10.32M derived: sum of 3 quarters · filed 2015-02-17 | $14.56M derived: sum of 4 quarters · filed 2015-02-17 |
| 2013-03-31 | $5.31M 10-Q · filed 2014-04-25 | $9.80M derived: sum of 2 quarters · filed 2015-02-17 | $14.04M derived: sum of 3 quarters · filed 2015-02-17 | $15.47M derived: sum of 4 quarters · filed 2015-02-17 |
| 2012-12-31 | $4.49M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-17 | $8.73M derived: sum of 2 quarters · filed 2015-02-17 | $10.16M derived: sum of 3 quarters · filed 2015-02-17 | $14.68M 10-K · filed 2015-02-17 |
| 2012-09-30 | $4.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-22 | $5.66M derived: sum of 2 quarters · filed 2013-10-22 | $10.18M 10-Q · filed 2013-10-22 | $12.18M derived: sum of 4 quarters · filed 2014-02-18 |
| 2012-06-30 | $1.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-23 | $5.95M 10-Q · filed 2013-07-23 | $7.94M derived: sum of 3 quarters · filed 2014-02-18 | $11.10M derived: sum of 4 quarters · filed 2014-02-18 |
| 2012-03-31 | $4.52M 10-Q · filed 2013-04-23 | $6.52M derived: sum of 2 quarters · filed 2014-02-18 | $9.67M derived: sum of 3 quarters · filed 2014-02-18 | $13.51M derived: sum of 4 quarters · filed 2014-02-18 |
| 2011-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-18 | $5.15M derived: sum of 2 quarters · filed 2014-02-18 | $8.99M derived: sum of 3 quarters · filed 2014-02-18 | $16.01M 10-K · filed 2014-02-18 |
| 2011-09-30 | $3.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-19 | $6.99M derived: sum of 2 quarters · filed 2012-10-19 | $14.01M 10-Q · filed 2012-10-19 | $18.84M derived: sum of 4 quarters · filed 2013-02-19 |
| 2011-06-30 | $3.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-20 | $10.85M 10-Q · filed 2012-07-20 | $15.69M derived: sum of 3 quarters · filed 2013-02-19 | $19.61M derived: sum of 4 quarters · filed 2013-02-19 |
| 2011-03-31 | $7.02M 10-Q · filed 2012-04-20 | $11.85M derived: sum of 2 quarters · filed 2013-02-19 | $15.77M derived: sum of 3 quarters · filed 2013-02-19 | $21.83M derived: sum of 4 quarters · filed 2013-02-19 |
| 2010-12-31 | $4.83M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-19 | $8.75M derived: sum of 2 quarters · filed 2013-02-19 | $14.81M derived: sum of 3 quarters · filed 2013-02-19 | $18.13M 10-K · filed 2013-02-19 |
| 2010-09-30 | $3.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-21 | $9.97M derived: sum of 2 quarters · filed 2011-10-21 | $13.29M 10-Q · filed 2011-10-21 | $14.64M derived: sum of 4 quarters · filed 2012-02-17 |
| 2010-06-30 | $6.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-22 | $9.37M 10-Q · filed 2011-07-22 | $10.71M derived: sum of 3 quarters · filed 2012-02-17 | $13.21M derived: sum of 4 quarters · filed 2012-02-17 |
| 2010-03-31 | $3.32M 10-Q · filed 2011-04-21 | $4.66M derived: sum of 2 quarters · filed 2012-02-17 | $7.16M derived: sum of 3 quarters · filed 2012-02-17 | |
| 2009-12-31 | $1.34M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-17 | $3.84M derived: sum of 2 quarters · filed 2012-02-17 | $5.19M 10-K · filed 2012-02-17 | |
| 2009-09-30 | $2.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-22 | $3.85M 10-Q · filed 2010-10-22 | ||
| 2009-06-30 | $1.35M 10-Q · filed 2010-07-23 | |||
| 2008-12-31 | $6.24M 10-K · filed 2011-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | United States | $6.510B | 26.31 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |